Page last updated: 2024-12-11

chlornaltrexamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chlornaltrexamine: RN given refers to (5alpha,6beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5486190
CHEMBL ID3228678
SCHEMBL ID1396491
MeSH IDM0067606

Synonyms (13)

Synonym
morphinan-3,14-diol, 6-(bis(2-chloroethyl)amino)-17-(cyclopropylmethyl)-4,5-epoxy-, (5-alpha,6-beta)-
beta-cna
brn 5405756
6beta-(bis(2-chloroethyl)amino)-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-3,14-diol
PDSP2_001725
chlornaltrexamine
67025-94-9
CHEMBL3228678
SCHEMBL1396491
NCGC00485834-01
6-[bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5-epoxymorphinan-3,14-diol
DTXSID90985877
Q263676

Research Excerpts

Overview

beta-Chlornaltrexamine (beta-CNA) is a non-equilibrium opioid receptor antagonist. It alkylates and inactivates opioid receptors.

ExcerptReferenceRelevance
"beta-Chlornaltrexamine (beta-CNA) is a non-equilibrium opioid receptor antagonist which alkylates and inactivates opioid receptors. "( Effects of beta-chlornaltrexamine on food intake, body weight and opioid-induced feeding.
Gosnell, BA; Grace, M; Levine, AS, 1987
)
1.13

Treatment

ExcerptReferenceRelevance
"beta-Chlornaltrexamine (20 nM) treatment and chronic morphine exposure resulted in a similar reduction in the maximal response to [N-MePhe3,D-Pro4]morphiceptin."( Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
Chavkin, C; Opheim, KE; Wimpey, TL, 1989
)
0.73

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In contrast, agonist-stimulated coupling was diminished (desensitization), resulting in a substantially flattened morphine dose-response curve."( Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.
Sadée, W; Surratt, CK; Wang, D, 2000
)
0.31
"8 mg/kg) produced a 74-fold increase in the ED(50) of morphine while showing no effect on bremazocine or BW373U86 dose-response curves."( Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear, JH; Burke, TF; Husbands, SM; Lewis, JW; Sumpter, TL; Traynor, JR; Woods, JH, 2000
)
0.5
" Microinjection of dynamin-DN and ConA also decreased the antinociceptive potency of the unlabeled opioid agonist dermorphin when microinjected into the vlPAG as demonstrated by rightward shifts in the dose-response curves."( Opioid receptor internalization contributes to dermorphin-mediated antinociception.
Aicher, SA; Arttamangkul, S; Bobeck, EN; Hegarty, DM; Ingram, SL; Macey, TA; Morgan, MM, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1123189Displacement of [3H]-naloxone from opioid receptor in rat brain homogenate at 1x10'-8 M preincubated for 5 mins measured after second washout by liquid scintillation counting analysis relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123194Analgesic activity in Swiss Webster mouse at 4.8 nmol, icv after 60 mins by tail flick test1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123207Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as increase in morphine ED50 at 1.2 nmol, icv after 24 hrs by tail flick test relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123200Toxicity in icv dosed Swiss Webster mouse assessed as lethargic behavior1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123188Displacement of [3H]-naloxone from opioid receptor in rat brain homogenate at 1x10'-8 M preincubated for 5 mins followed by washout measured after 15 mins by liquid scintillation counting analysis relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123210Effect on development of dependence to morphine in Swiss Webster mouse assessed as increase in naloxone ED50 for eliciting withdrawal jumping at 0.24 nmol, icv after 24 hrs relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123201Toxicity in icv dosed Swiss Webster mouse assessed as suppression of startle reflex to loud and abrupt auditory stimulus1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123211Effect on development of dependence to morphine in Swiss Webster mouse assessed as increase in naloxone ED50 for eliciting withdrawal jumping at 0.24 nmol, icv after 72 hrs relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123202Toxicity in icv dosed Swiss Webster mouse assessed as decrease in locomotor activity1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123191Displacement of [3H]-naloxone from opioid receptor in rat brain homogenate at 1x10'-8 M preincubated for 5 mins measured after fourth washout by liquid scintillation counting analysis relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123209Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as change in morphine ED50 at 1.2 nmol, icv after 10 mins in presence of naloxone1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123204Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as change in morphine ED50 at 2.4 nmol, icv after 2 hrs by tail flick test1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123190Displacement of [3H]-naloxone from opioid receptor in rat brain homogenate at 1x10'-8 M preincubated for 5 mins measured after third washout by liquid scintillation counting analysis relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123198Toxicity in Swiss Webster mouse assessed as mortality at 2.4 nmol, icv1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123193Analgesic activity in Swiss Webster mouse at 4.8 nmol, icv after 10 to 20 mins by tail flick test relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123196Toxicity in Swiss Webster mouse assessed as lethality at 4.8 nmol, icv after 1.5 hrs1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123203Toxicity in icv dosed Swiss Webster mouse assessed as change in tail flick latency1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123208Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as increase in morphine ED50 at 1.2 nmol, icv after 72 hrs by tail flick test relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123192Analgesic activity in Swiss Webster mouse at 0.6 to 4.8 nmol, icv after 2 hrs by tail flick test1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123205Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as increase in morphine ED50 at 0.6 nmol, icv after 2 hrs by tail flick test1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123206Inhibition of morphine-induced analgesia in Swiss Webster mouse assessed as increase in morphine ED50 at 1.2 nmol, icv after 2 hrs by tail flick test relative to control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
AID1123197Toxicity in Swiss Webster mouse assessed as tonic convulsions at 4.8 nmol, icv1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (57.33)18.7374
1990's13 (17.33)18.2507
2000's12 (16.00)29.6817
2010's5 (6.67)24.3611
2020's2 (2.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.97 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other78 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]